Ocera Therapeutics, Inc. (NASDAQ:OCRX) has received a consensus recommendation of “Hold” from the six analysts that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $4.50.

Several equities research analysts have recently weighed in on the company. HC Wainwright reissued a “buy” rating and set a $4.00 target price on shares of Ocera Therapeutics in a research report on Thursday, March 16th. Aegis reissued a “buy” rating and set a $3.00 target price on shares of Ocera Therapeutics in a research report on Saturday, March 11th. Finally, Zacks Investment Research downgraded Ocera Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 17th.

Shares of Ocera Therapeutics (NASDAQ OCRX) traded down 1.03% during mid-day trading on Monday, hitting $0.96. 327,065 shares of the stock were exchanged. The stock’s market cap is $25.45 million. The stock’s 50 day moving average is $1.13 and its 200-day moving average is $1.39. Ocera Therapeutics has a 12 month low of $0.52 and a 12 month high of $3.15.

Ocera Therapeutics (NASDAQ:OCRX) last issued its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.24) by $0.04. Ocera Therapeutics had a negative return on equity of 148.87% and a negative net margin of 4,416.26%. On average, analysts anticipate that Ocera Therapeutics will post ($1.10) EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Ocera Therapeutics, Inc. (OCRX) Receives Average Rating of “Hold” from Analysts” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/06/16/analysts-set-ocera-therapeutics-inc-ocrx-target-price-at-4-50-updated-updated.html.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Hikari Power Ltd purchased a new position in Ocera Therapeutics during the first quarter worth about $328,000. Renaissance Technologies LLC increased its position in shares of Ocera Therapeutics by 17.9% in the fourth quarter. Renaissance Technologies LLC now owns 219,100 shares of the biopharmaceutical company’s stock valued at $460,000 after buying an additional 33,300 shares during the period. Vanguard Group Inc. increased its position in shares of Ocera Therapeutics by 521.3% in the first quarter. Vanguard Group Inc. now owns 1,079,750 shares of the biopharmaceutical company’s stock valued at $1,415,000 after buying an additional 905,957 shares during the period. Interwest Venture Management Co. bought a new position in shares of Ocera Therapeutics during the fourth quarter valued at $2,621,000. Finally, Perceptive Advisors LLC bought a new position in shares of Ocera Therapeutics during the first quarter valued at $2,817,000. Hedge funds and other institutional investors own 24.35% of the company’s stock.

Ocera Therapeutics Company Profile

Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger.

Receive News & Stock Ratings for Ocera Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocera Therapeutics Inc. and related stocks with our FREE daily email newsletter.